gastrointestinal%20stromal%20tumor
GASTROINTESTINAL STROMAL TUMOR
Gastrointestinal stromal tumors are morphologically spindle cell, epithelioid, or occasionally pleomorphic mesenchymal tumors of the gastrointestinal tract.
Signs and symptoms of gastrointestinal tumor include presence of abdominal mass (which may be an incidental finding in endoscopy), gastrointestinal bleeding, hemoperitoneum, anemia and gastrointestinal perforation.

Follow Up

  • Relapses affect the liver & peritoneum & rarely the bone
    • Risk of relapse is high w/ ruptured tumors
  • Evaluate tumor response by checking for tumor shrinkage, tumor density changes on computed tomography (CT) scan, & absence of tumor progression
  • For gastrointestinal stromal tumors (GISTs) <2 cm w/o high-risk endoscopic ultrasound (EUS) features, consider endoscopic surveillance every 6-12 months

Post-surgery

Completely Resected Tumors w/ or w/o Pre-operative Imatinib

  • Clinical evaluation every 3-6 months x 5 years, then annually
    • May be less frequent for small tumors (<2 cm)
  • Abdominal/Pelvic CT every 3-6 months x 3-5 years, then annually

Metastatic Disease or Persistent Gross Residual Disease w/ or w/o Pre-op Imatinib

  • Clinical evaluation & abdominal/pelvic CT every 3-6 months
    • May be less frequent for small tumors (<2 cm)

Management of Disease Progression

Limited Disease Progression

  • Continue or increase Imatinib dose as tolerated or may change to Sunitinib & reassess tumor response via positron emission tomography (PET) or CT
  • For progressing lesions while continuing Imatinib, consider surgical resection if still feasible, radiofrequency ablation or embolization, or palliative radiation therapy for bone metastases

Systemic Disease Progression

  • Increase Imatinib dose as tolerated or may change to Sunitinib & assess response via PET or CT
  • If still w/ limited or systemic disease progression, consider Regorafenib, a clinical trial or supportive care
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 May 2014

New drug applications approved by US FDA as of 15-30 May which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

28 Apr 2017
Silymarin does not appear to be significantly better than placebo in reducing disease activity by 30 percent or more in patients with nonalcoholic steatohepatitis (NASH), according to the results of a trial.
08 May 2017
Transabdominal bowel wall ultrasonography shows utility in monitoring disease activity in patients with active Crohn’s disease (CD), according to a study. The imaging technique is ideal for evaluating early transmural changes in disease activity, in response to medical treatment.